Get the Stockscreener App
88.33
1.31%
-1.17
After Hours:
88.33
Apogee Therapeutics Inc stock is traded at $88.33, with a volume of 1.30M.
It is down -1.31% in the last 24 hours and up +6.51% over the past month.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$89.50
Open:
$89.46
24h Volume:
1.30M
Relative Volume:
1.36
Market Cap:
$6.66B
Revenue:
-
Net Income/Loss:
$-274.62M
P/E Ratio:
-20.41
EPS:
-4.3278
Net Cash Flow:
$-235.37M
1W Performance:
+1.62%
1M Performance:
+6.51%
6M Performance:
+14.60%
1Y Performance:
+111.01%
1-Day Range:
$87.39
$91.24
1-Week Range:
$81.04
$91.24
52-Week Range:
$34.34
$95.31
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
88.33 | 6.66B | 0 | -274.62M | -235.37M | -4.3278 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Hold |
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
Apogee Therapeutics CEO Michael Henderson sells $1.67m in stock - Investing.com
Apogee Therapeutics shareholders elect directors and approve proposals at annual meeting - Investing.com India
Apogee Therapeutics (APGE) CEO sells 20,000 shares in planned trades, keeps over 1.09M - Stock Titan
Apogee Therapeutics (NASDAQ: APGE) investors back board, pay and auditor - Stock Titan
Apogee Therapeutics (APGE) links 7,657-share option grant to director - Stock Titan
Apogee Therapeutics (APGE) director receives stock options for 7,657 shares - Stock Titan
Apogee Therapeutics (APGE) director Lisa Bollinger granted 7,657 stock options - Stock Titan
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Shah Nimish P - Moomoo
Goldman Sachs Maintains Apogee Therapeutics(APGE.US) With Hold Rating, Maintains Target Price $89 - Moomoo
APGE Stock Price, Quote & Chart - ChartMill
Apogee Therapeutics Maps Phase 3 Push for Zumilokibart, Backed by Blackstone Funding - Yahoo Finance
These 10 mid-cap US healthcare companies carry the market's most expensive valuations - MSN
TD Asset Management Inc Has $9.76 Million Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Behavioral Patterns of APGE and Institutional Flows - Stock Traders Daily
APGE Maintained by RBC Capital -- Price Target Raised to $97.00 - GuruFocus
RBC Capital raises Apogee Therapeutics stock price target to $97 By Investing.com - Investing.com Australia
RBC Raises Price Target on Apogee Therapeutics to $97 From $82, Keeps Sector Perform, Speculative Risk - marketscreener.com
RBC Capital raises Apogee Therapeutics stock price target to $97 - Investing.com
Apogee Therapeutics CMO Dambkowski sells $432,904 in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics CMO Dambkowski sells $432,904 in stock - Investing.com
Apogee Therapeutics (APGE) CMO trades stock under Rule 10b5-1 plan - Stock Titan
Blackstone pledges $1.3 billion to help develop Apogee skin drug - MSN
Apogee (APGE) Secures Up to $1.3B in Non-Dilutive Financing from Blackstone to Advance Zumilokibart - Insider Monkey
Should Positive Phase 2 Zumilokibart Data and Blackstone Funding Reshape the Outlook for Apogee Therapeutics (APGE) Investors? - Sahm
Apogee Therapeutics readies Zumi for phase 3 with Blackstone backing - MSN
Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing - sharewise.com
APGE: Strong phase II-B results and a $1.3B Blackstone deal drive late-stage and combo program expansion - TradingView
Deutsche Bank Adjusts PT on Apogee Therapeutics to $116 From $118, Maintains Buy Rating - marketscreener.com
Apogee Therapeutics (APGE) Among Most Expensive U.S. Healthcare Stocks by Valuation - GuruFocus
These 10 mid-cap U.S. healthcare companies carry the market's most expensive valuations - Seeking Alpha
Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 2 APEX Results For Zumilokibart - Yahoo Finance
Apogee Therapeutics shares surge following $1.3 billion Blackstone financing partnership (APOG) - MSN
Latham & Watkins Advises Apogee Therapeutics in US$1.3 Billion Strategic Financing Collaboration With Blackstone Life Sciences, One of the Largest Life Sciences Financings of 2026 - Legal Desire
Apogee falls following Phase 2 results for zumilokibart in atopic dermatitis - MSN
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic DermatitisSlideshow (NASDAQ:APGE) 2026-05-30 - Seeking Alpha
A Quick Look at Today's Ratings for Apogee Therapeutics(APGE.US), With a Forecast Between $81 to $131 - Moomoo
Analysts Offer Insights on Healthcare Companies: Agilent (A), Apogee Therapeutics (APGE) and Pfizer (PFE) - The Globe and Mail
(APGE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Apogee Stock in Focus After Blackstone Announces $1.3 Billion Deal - Bez Kabli
Apogee Therapeutics to Participate in Upcoming June Conferences - The Manila Times
Apogee Therapeutics: Charging Toward Pivotal Eczema Trial With Extended Dosing (APGE) - Seeking Alpha
Apogee Therapeutics lines up $1.3B strategic financing for zumilokibart program - Yahoo Finance
Apogee Therapeutics Soars After $1.3B Deal with Blackstone Life Sciences - StockInvest.us
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):